MedTrace Logo

CHInese Medicine NeuroAid Efficacy on Stroke Recovery

NCT00554723 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1100

Last updated 2014-05-01

No results posted yet for this study

Summary

CHIMES is a double blind, placebo controlled, randomized, multicenter study to test the hypothesis that NeuroAid is superior to placebo in reducing neurological deficit and improving functional outcome in patients with cerebral infarction of an intermediate range of severity.

Conditions

Interventions

DRUG

NeuroAid

4 capsules 3 times daily, for three months

DRUG

NeuroAid matched Placebo

NeuroAid matched Placebo, 4 capsules 3 times daily, for three months

Sponsors & Collaborators

  • National Medical Research Council (NMRC), Singapore

    collaborator OTHER_GOV

  • CHIMES Society

    lead OTHER

Principal Investigators

  • Marie Germaine Bousser, MD · APHP Paris

  • Christopher Chen, MBBS · National University of Singapore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Hong Kong
  • Malaysia
  • Philippines
  • Singapore
  • Sri Lanka
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00554723 on ClinicalTrials.gov